← Back to Screener
Nautilus Biotechnolgy, Inc. Common Stock (NAUT)
Price$2.96
Favorite Metrics
Price vs S&P 500 (26W)247.47%
Price vs S&P 500 (4W)-9.49%
Market Capitalization$383.49M
All Metrics
Book Value / Share (Quarterly)$1.24
P/TBV (Annual)1.19x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.41
Price vs S&P 500 (YTD)51.25%
EPS (TTM)$-0.47
10-Day Avg Trading Volume0.32M
EPS Excl Extra (TTM)$-0.47
EPS (Annual)$-0.47
ROI (Annual)-37.59%
Cash / Share (Quarterly)$0.82
ROA (Last FY)-30.87%
EBITD / Share (TTM)$-0.52
ROE (5Y Avg)-25.55%
Cash Flow / Share (Annual)$-0.41
P/B Ratio2.44x
P/B Ratio (Quarterly)1.57x
Net Income / Employee (Annual)$-0
ROA (TTM)-28.34%
EPS Incl Extra (Annual)$-0.47
Current Ratio (Annual)13.33x
Quick Ratio (Quarterly)13.00x
3-Month Avg Trading Volume0.27M
52-Week Price Return318.91%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.22
52-Week High$4.31
EPS Excl Extra (Annual)$-0.47
CapEx CAGR (5Y)6.78%
26-Week Price Return256.22%
Quick Ratio (Annual)13.00x
13-Week Price Return57.81%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)13.33x
Enterprise Value$371.102
Book Value / Share Growth (5Y)14.37%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.82
3-Month Return Std Dev106.84%
Net Income / Employee (TTM)$-0
ROE (Last FY)-37.59%
EPS Basic Excl Extra (Annual)$-0.47
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.47
ROI (TTM)-33.64%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.52
Price vs S&P 500 (52W)283.82%
Year-to-Date Return55.38%
5-Day Price Return2.02%
EPS Normalized (Annual)$-0.47
ROA (5Y Avg)-22.01%
Month-to-Date Return-21.91%
Cash Flow / Share (TTM)$-0.47
EBITD / Share (Annual)$-0.52
ROI (5Y Avg)-25.55%
EPS Basic Excl Extra (TTM)$-0.47
P/TBV (Quarterly)1.35x
P/B Ratio (Annual)1.57x
Book Value / Share (Annual)$1.24
Price vs S&P 500 (13W)54.95%
Beta0.85x
Revenue / Share (TTM)$0.00
ROE (TTM)-33.64%
52-Week Low$0.62
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.25
4.25
4.25
Industry Peers — Lab Analytical Instruments(23)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
NAUTNautilus Biotechnolgy, Inc. Common Stock | — | — | — | — | $2.96 |
AAgilent Technologies Inc. | 4.83x | 5.41% | 52.60% | 20.40% | $120.96 |
WATWaters Corp | 10.18x | 6.00% | 59.28% | 25.36% | $335.61 |
MTDMettler-Toledo International | 6.66x | 5.47% | 59.37% | 26.05% | $1324.66 |
ILMNIllumina Inc | 4.69x | 6.04% | 66.61% | 18.44% | $132.86 |
RVTYRevvity, Inc. | 3.64x | -5.46% | 54.77% | 12.49% | $93.03 |
BIOBio-Rad Laboratories, Inc.Class A | 3.17x | 0.29% | 52.01% | 1.59% | $303.34 |
BIO.BBio-Rad Laboratories, Inc. Class B | 3.17x | 0.29% | 52.01% | 1.59% | $277.00 |
BRKRBruker Corporation | 1.81x | 11.57% | 47.13% | 1.40% | $41.10 |
BRKRPBruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A | 1.81x | 11.57% | 47.13% | 1.40% | $320.13 |
AVTRAvantor, Inc. | 0.88x | 0.49% | 32.65% | -3.83% | $8.50 |
About
Nautilus Biotechnology develops a platform technology for high-throughput proteomics analysis, providing researchers with integrated tools to study the human proteome at scale. The company's offerings include proprietary mass spectrometry systems, reagent kits, and analysis software designed for research, diagnostics, and drug development. As a development-stage company, Nautilus aims to expand access to comprehensive protein analysis and accelerate advances in human health and medicine.